Back to School: How biopharma can reboot drug development. Access exclusive analysis here

MorphoSys signs transformational deal

MorphoSys (FSE:MOR) and Novartis (NVS; SWX:NOVN) signed an antibody deal that should fund the biotech's next stages of internal

Read the full 196 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE